Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that CRSwNP has been helping to drive increased sales of Dupixent, which is approved for a range of ...
Zacks.com on MSN3mon
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary GoalsBesides Dupixent, Nucala faces strong competition ... AZN is also evaluating Fasenra in late-stage studies for treating nasal ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...
doesn’t matter if their breakthrough drug Dupixent is indicated for seven gigantic illnesses, asthma, eczema, [and] nasal polyps. This company has never lost its ability to develop new medicines ...
The SWIFT studies achieved their co-primary endpoints – treatment with depemokimab led to a statistically significant reduction in nasal polyp size ... the FDA expanded Dupixent’s label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback